NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

CompletedPhase 3

Sponsor: Hoffmann-La Roche

Conditions: Diabetic Macular Edema

Interventions: Aflibercept, Faricimab, Sham Procedure

Countries: United States, Argentina, Australia, Brazil, Canada, China, Czechia, Denmark

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
* Hemoglobin A1c (HbA1c) of less than or equal to (≤)10% within 2 months prior to Day 1
* Macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea
* Decreased visual acuity attributable primarily to DME
* Ability and willingness to undertake all scheduled visits and assessments
* For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment

Exclusion Criteria:

* Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1
* Uncontrolled blood pressure, defined as a systolic value greater than (\>)180 millimeters of mercury (mmHg) and/or a diastolic value \>100 mmHg while a patient is at rest
* Currently pregnant or breastfeeding, or intend to become pregnant during the study
* Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye
* Any intraocular or periocular corticosteroid treatment within 6 months prior to Day 1 to the study eye
* Prior administration of IVT faricimab in either eye
* Active intraocular or periocular infection or active intraocular inflammation in the study eye
* Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
* Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
* Other protocol-specified inclusion/exclusion criteria may apply

Locations (188)

Phoenix, Arizona, United States
Phoenix, Arizona, United States
Springdale, Arkansas, United States
Bakersfield, California, United States
Beverly Hills, California, United States
Encino, California, United States
Fullerton, California, United States
Mountain View, California, United States
Sacramento, California, United States
Santa Barbara, California, United States
Santa Maria, California, United States
Walnut Creek, California, United States
Aurora, Colorado, United States
Colorado Springs, Colorado, United States
Waterford, Connecticut, United States
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
Melbourne, Florida, United States
Palm Beach Gardens, Florida, United States
Plantation, Florida, United States
St. Petersburg, Florida, United States
Augusta, Georgia, United States
Oak Forest, Illinois, United States
Springfield, Illinois, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Las Vegas, Nevada, United States
Bloomfield, New Jersey, United States
+ 158 more on CT.gov